Opportunities for overcoming tuberculosis: Emerging targets and their inhibitors.

Liu Yang, Xueping Hu, Xin Chai, Qing Ye, Jinping Pang, Dan Li, Tingjun Hou

Drug discovery today 2022 Jan

filter terms:

Tuberculosis (TB), an airborne infectious disease mainly caused by Mycobacterium tuberculosis (Mtb), remains a leading cause of human morbidity and mortality worldwide. Given the alarming rise of resistance to anti-TB drugs and latent TB infection (LTBI), new targets and novel bioactive compounds are urgently needed for the treatment of this disease. We provide an overview of the recent advances in anti-TB drug discovery, emphasizing several newly validated targets for which an inhibitor has been reported in the past five years. Our review presents several attractive directions that have potential for the development of next-generation therapies. Copyright © 2021 Elsevier Ltd. All rights reserved.

Citation

Liu Yang, Xueping Hu, Xin Chai, Qing Ye, Jinping Pang, Dan Li, Tingjun Hou. Opportunities for overcoming tuberculosis: Emerging targets and their inhibitors. Drug discovery today. 2022 Jan;27(1):326-336